Gastro Medical News about colorectal

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Survival and recurrence after neo-adjuvant chemotherapy and liver resection for colorectal metastases – A 10-year study
European Journal of Surgical Oncology, 06/26/09

Karanjia ND et al. - In a study to assess the outcome of colorectal liver metastases (CRLM) treated by a combination of neo-adjuvant chemotherapy and surgery, it was determined that neo-adjuvant chemotherapy followed by liver surgery is associated with improved survival and low CIRM and re-resection rates.

Methods

283 consecutive pts underwent liver resection for CRLM over 10 yrs with curative intent.
Pts received chemotherapy preoperatively for synchronous and early (<2 yrs) metachronous metastases.
Univariate and multivariate analyses were used to identify mortality risk factors.

Results

Overall survival (OS) at 1, 3, and 5 yrs was 90%, 59.2% and 46.1%, respectively.
Disease free survival at 1, 3, and 5 yrs was 68.1%, 34.8%, and 27.9%, respectively.
Operative mortality was 2.1% and morbidity was 23.7%.
Pts with macroscopic diaphragm invasion by tumour, CEA >100 ng/ml, tumour size >5 cm or cancer involved resection margins (CIRM) had a significantly worse OS.
Incidence of CIRM and re-resection was 4.9% and 4.5%, respectively.

<< Previous
Thyroid Hormone-Related Regulation of Gene Expression in Human...

Next >>
Surgical specialty, surgical unit volume, and mortality after...